Search
Atazanavir
go.drugbank.com/drugs/DB01072ApprovedInvestigationalAtazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from o...
Products: ATAZANAVIR EGCabazitaxel
go.drugbank.com/drugs/DB06772ApprovedInvestigational[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376] … [A7056] Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].
Products: CABAZITAXEL EGHexylresorcinol
go.drugbank.com/drugs/DB11254ApprovedHexylresorcinol is a substituted dihydroxybenzene. It exhibits antiseptic, anthelmintic, and local anesthetic properties. It can be found in topical applications for minor skin infections and in oral solutions or throat lozenges for pain...
Products: -s.miel Et Eucalypt.Ticlopidine
go.drugbank.com/drugs/DB00208ApprovedTiclopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlo...
Products: TICLOPIDINA EGDarifenacin
go.drugbank.com/drugs/DB00496ApprovedInvestigationalDarifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it...
Products: DARUCIL® ER 15 MGDeflazacort
go.drugbank.com/drugs/DB11921ApprovedDeflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. Duchenne Muscular Dyst...
Products: DEFLAZACORT EGFlecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawnFlecainide is a Class I anti-arrhythmic agent like encainide and propafenone. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ...
Products: FLECAINIDE EGSilodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α1A subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the...
Products: SILODOSINA EGCyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigationalCyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepre...
Mixtures: RODALGIN COMPLEX TABLETASProducts: Cyclobenzaprine HCL ERPropafenone
go.drugbank.com/drugs/DB01182ApprovedInvestigationalAn antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Products: PROPAFENONE EG